Three dose regimens of fulvestrant in postmenopausal Japanese women with advanced breast cancer: results from a double-blind, phase II comparative study (FINDER1)

Addo, 2002, A phase I trial to assess the pharmacology of the new oestrogen receptor antagonist fulvestrant on the endometrium in healthy postmenopausal volunteers, Br J Cancer, 87, 1354, 10.1038/sj.bjc.6600644 DeFriend, 1994, Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer, Cancer Res, 54, 408 Robertson, 2001, Comparison of the short-term biological effects of 7alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl]estra-1,3,5, (10)-triene-3,17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer, Cancer Res, 61, 6739 Wakeling, 2000, Similarities and distinctions in the mode of action of different classes of antioestrogens, Endocr Relat Cancer, 7, 17, 10.1677/erc.0.0070017 Chia, 2008, Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT, J Clin Oncol, 26, 1664, 10.1200/JCO.2007.13.5822 Howell, 2002, Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment, J Clin Oncol, 20, 3396, 10.1200/JCO.2002.10.057 Howell, 2005, Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma: a prospectively planned combined survival analysis of two multicenter trials, Cancer, 104, 236, 10.1002/cncr.21163 Robertson, 2003, Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials, Cancer, 98, 229, 10.1002/cncr.11468 Howell, 2006, Fulvestrant (‘Faslodex'): current and future role in breast cancer management, Crit Rev Oncol Hematol, 57, 265, 10.1016/j.critrevonc.2005.08.001 Osborne, 2002, Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial, J Clin Oncol, 20, 3386, 10.1200/JCO.2002.10.058 Robertson, 2007, Fulvestrant (Faslodex)—how to make a good drug better, Oncologist, 12, 774, 10.1634/theoncologist.12-7-774 Fujiwara, 2007, Tolerability of fulvestrant high-dose (HD) in postmenopausal Japanese women with hormone receptor-positive (HR+) advanced (ABC) or recurrent breast cancer (RBC) Kuter, 2007, Fulvestrant 500 mg vs 250 mg: first results from NEWEST, a randomized, phase II neoadjuvant trial in postmenopausal women with locally advanced, estrogen receptor-positive breast cancer, Breast Cancer Res Treat, 106 Simon, 1985, Randomized phase II clinical trials, Cancer Treat Rep, 69, 1375 Kuter, 2008, Pharmacokinetic profile of fulvestrant 500 mg vs 250 mg: results from the NEWEST study, J Clin Oncol, 26, 10.1200/jco.2008.26.15_suppl.579 McCormack, 2008, Pharmacokinetic profile of the fulvestrant loading dose regimen in postmenopausal women with hormone receptor-positive advanced breast cancer, Clin Breast Cancer, 8, 347, 10.3816/CBC.2008.n.040 Robertson, 2004, Pharmacokinetic profile of intramuscular fulvestrant in advanced breast cancer, Clin Pharmacokinet, 43, 529, 10.2165/00003088-200443080-00003 Robertson, 2009, Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study, J Clin Oncol, 27, 4530, 10.1200/JCO.2008.21.1136 Di Leo, 2009, CONFIRM: a phase III, randomized, parallel-group trial comparing fulvestrant 250 mg vs fulvestrant 500mg in postmenopausal women with estrogen receptor-positive advanced breast cancer, Breast Cancer Res, 69, 491s